On 3rd March, 2020 Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced an accelerated timeline for developing its DNA vaccine INO-4800 to address COVID-19, the respiratory infection the World Health Organization (WHO) has designated a Public Health Emergency of International Concern of the highest level. According to WHO, approximately 89,000 cases have been reported globally with more than 3,000 deaths.
Dr. J. Joseph Kim, Inovio’s President & CEO, shared this accelerated timeline at the U.S. Coronavirus Task Force meeting at the White House on March 2. Dr. Kim said, “Inovio is the leader in coronavirus vaccine development and the only company with a Phase 2 vaccine for a related coronavirus that causes Middle East Respiratory Syndrome (MERS). Using our modern DNA medicines platform, we designed our DNA vaccine INO-4800 in three hours after the publication of the genetic sequence of the novel coronavirus that causes COVID-19.”
Dr. Kim continued, “We immediately began preclinical testing and small-scale manufacture and have already shared robust preclinical data with our public and private partners. We plan to begin human clinical trials in the U.S. in April and soon thereafter in China and South Korea, where the outbreak is impacting the most people. We plan on delivering one million doses by year end with existing resources and capacity. However, we will need additional resources to scale up to make enough doses to help protect Americans from COVID-19 as well as to lead global efforts to curtail this virus.”
Total Revenue for Inovio Pharmaceuticals, Inc. (INO) is $6.34M. Gross Profit is $-64.78M and the EBITDA is $-103.22M.
The average 10-day trading volume of Inovio Pharmaceuticals, Inc. (INO) is 33.49M compared to 9.79M over the last 3 months which indicates a lower amount in trading activity. Right now, Inovio Pharmaceuticals, Inc. (INO) has a 50-day moving average of $3.97 and a 200-day moving average of $2.86. These moving averages are popular technical indicators that investors use to analyze price trends of Inovio Pharmaceuticals, Inc. (INO).
Approximately 13.52% of the shares of the company are short sold from investors betting the stock may trade lower. The beta value of Inovio Pharmaceuticals, Inc. (INO) stock is 2.16, indicating its 25.35% to 14.85% more volatile than the overall market.
INO is trading 289.03% off its 52 week low at $1.91 and 25.21% off its 52 week high of $5.95. Performance wise, INO stock has recently shown investors 99.46% an increase in a week, 64.46% an increase in a month and 195.63% an increase in the past quarter.
Furthermore, Inovio Pharmaceuticals, Inc. (INO) has shown a return of 125.76% since the beginning of the year.
On Oct-18-17 RBC Capital Mkts Initiated INO as Outperform at $11. On Feb-15-18 Maxim Group Reiterated INO as Buy at $12 → $8 and on Dec-19-19 ROTH Capital Initiated INO as Buy at $13.
There are currently 96.23M shares in the float and 101.87M shares outstanding. There are 13.52% shares short in INOs float.
The industry rank for Inovio Pharmaceuticals, Inc. (INO) is 105 out of 255 ranking it at the Top 41% .
INO last 2 years revenues have increased from $30,482 to $6,335 showing an uptrend.
Wall Street expects Inovio Pharmaceuticals, Inc. (INO) to report an EPS next Qtr loss of -0.24 and a profit of 25.00% next year.
The growth rate on INO this year is -2.86 compared to an industry 7.90. INOs next year’s growth rate is 25.93 compared to an industry 10.00.
The book value per share (mrq) is 0.34 and cash per share (mrq) is 0.92. Giving them a price/book (mrq) of 20.43 compared to an industry of 3.51
INO fundamental ratios shows an EPS growth vs. previous year -1.08 and EPS growth vs. previous quarter -0.23.